Nyrada, Inc. · ASX:NYR
Nyrada — Shareholder Meeting (November 2025)
19 slides from Nyrada's shareholder meeting presentation, Nov 10, 2025
Slide 1: Investor Presentation and CEO AGM Presentation
10 November 2025 Sydney, Australia Investor Presentation and CEO AGM Presentation Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions provides the enclosed presentation sli
Slide 2: About Nyrada Inc.
About Nyrada Inc. Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company’s lead candidate, Xolatryp™, has shown efficacy in b
Slide 3: AGM Presentation
For personal use only AGM Presentation James Bonnar Managing Director and CEO 12 November 2025 | Sydney, Australia Improving Lives, Offering Hope ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 4: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 5: Nyrada Overview
Nyrada Overview › Clinical-stage biotech company developing TRPC ion For personal use only channel inhibitors to treat a range of medical conditions › Lead drug candidate – Xolatryp (formerly NYR-BI03). › Potent 3rd generation TRPC 3, 6 and 7 channel inhibitor › Novel and well-understood mechanism o
Slide 6: Company Snapshot
Company Snapshot Company Structure Leadership For personal use only * Excludes options to be considered at 12 November 2025 Annual General Meeting Share Register – 6 November 25 Price Chart 4
Slide 7: Origins of TRPC Channel Inhibition
Origins of TRPC Channel Inhibition Lutz Birnbaumer Birnbaumer’s Mice For personal use only 5
Slide 8: TRPC Channels - Cardioprotection
TRPC Channels - Cardioprotection For personal use only Cell Type TRPC Activation Effect Xolatryp Inhibition Effect Cardiomyocytes Calcium overload → cell death Prevents damage, preserves function and contractility Endothelial Impaired repair → poor blood flow Enhances vessel repair, reduces inflamma
Slide 9: Ischemia Reperfusion – Last Cardiac Frontier
Ischemia Reperfusion – Last Cardiac Frontier For personal use only PCI (Balloon Angioplasty): • First procedure in 1977, stents in 1994, • Standard of care for STEMI by early 2000s 7
Slide 10: Large Market Opportunity – Myocardial Ischemia Reperfusion Injury
Large Market Opportunity – Myocardial Ischemia Reperfusion Injury For personal use only Globally: ~15-20 million ~15% people suffer heart mortality within 30 attack annually days No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs associated wit
Slide 11: Preclinical Study
Preclinical Study 1 Key Preclinical Results: Xolatryp showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shorte
Slide 12: Preclinical Study
Preclinical Study 2 Key Preclinical Results: For personal use only Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion • 42% Cardioprotection • 88% decrease in arrhythmias at 1
Slide 13: Phase I Clinical Trial
Phase I Clinical Trial Key Results: For personal use only Xolatryp met its Primary Endpoint with all doses safe and well tolerated, with no dose-limiting, or dose-related safety issues. • 48 healthy participants (36 received drug, 12 received placebo). • Nil SAEs • 10 AEs • All mild or moderate • 5
Slide 14: Phase IIa Clinical Trial
Phase IIa Clinical Trial Key Features: For personal use only Xolatryp to be assessed for safety and preliminary efficacy in patients with ST-Elevation Myocardial Infarction (STEMI) who undergo primary Percutaneous Coronary Intervention (PCI) Primary End Point – Safety Further End Points – Explorator
Slide 15: R&D Activities
R&D Activities Evolving Pipeline: For personal use only Xolatryp demonstrated preclinical efficacy: • Myocardial ischemia reperfusion injury • Ischemic stroke • Moderate to severe TBI Literature suggests Xolatryp may have efficacy in: • Protection from cardiotoxicity (induced by anti-cancer drugs) •
Slide 16: Poised for Value Inflection
Poised for Value Inflection For personal use only Source: Karst Peak Rx - www.kp-rx.com 14
Slide 17: Financial Overview and Outlook
Financial Overview and Outlook For personal use only FY2025 Highlights and FY2026 Outlook Operating Results Summary › Resources FY2025 FY2023 (AU$) (AU$) › Cash balance of AU$7.92 million at 30 September 2025 R&D Costs 4,376,215 2,030,502 › Expected R&D rebate of AU$2.16 Corporate and admin million
Slide 18: Conclusion
Conclusion › Nyrada – the company For personal use only › Pioneering TRPC channel inhibition therapies to treat a range of medical conditions › AU$7.92 million cash position at end Sep 2025 › AU$8.25 million capital raised in Aug 2025 › AU$2.16 million R&D rebated expected in Dec 2025 › Xolatryp – t
Slide 19: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 17